Poly Medicure Intrinsic Value
POLYMED Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹797.28 | ₹637.82 - ₹956.74 | -55.1% | EPS: ₹36.24, Sector P/E: 22x |
| Book Value Method | asset | ₹1084.71 | ₹976.24 - ₹1193.18 | -38.9% | Book Value/Share: ₹542.35, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹751.37 | ₹676.23 - ₹826.51 | -57.7% | Revenue/Share: ₹375.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1170.25 | ₹1053.23 - ₹1287.28 | -34.1% | EBITDA: ₹600.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹710.52 | ₹568.42 - ₹852.62 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹532.89 | ₹479.60 - ₹586.18 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹559.91 | ₹503.92 - ₹615.90 | -68.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹888.15 | ₹799.34 - ₹976.97 | -50.0% | ROE: 13.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹665.01 | ₹598.51 - ₹731.51 | -62.6% | EPS: ₹36.24, BVPS: ₹542.35 |
Want to compare with current market value? Check POLYMED share price latest .
Valuation Comparison Chart
POLYMED Intrinsic Value Analysis
What is the intrinsic value of POLYMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Poly Medicure (POLYMED) is ₹751.37 (median value). With the current market price of ₹1776.30, this represents a -57.7% variance from our estimated fair value.
The valuation range spans from ₹532.89 to ₹1170.25, indicating ₹532.89 - ₹1170.25.
Is POLYMED undervalued or overvalued?
Based on our multi-method analysis, Poly Medicure (POLYMED) appears to be trading above calculated value by approximately 57.7%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 33.63 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.15 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 13.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Poly Medicure
Additional stock information and data for POLYMED
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹240 Cr | ₹-357 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹266 Cr | ₹146 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹191 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹124 Cr | ₹82 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹119 Cr | ₹-99 Cr | Positive Operating Cash Flow | 6/10 |